1.
CTHRC1 is associated with BRAF(V600E) mutation and correlates with prognosis, immune cell infiltration, and drug resistance in colon cancer, thyroid cancer, and melanoma. Biomol Biomed. 2024;25(1):42–61. doi:10.17305/bb.2024.10397